SDPA Fall | Live Blog | Product Theater Sponsored by Janssen Biotech, Inc.
Product Theater | “Perspectives on a Biologic Therapy for the Treatment of Moderate to Severe Plaque Psoriasis: Patient-Provider-Practice”
Sponsored by: Janssen Immunology
Presented by: Dr. Craig Kraffert, MD
The need for new treatment options for psoriasis is driven by dissatisfaction in care of psoriasis patients. During the SDPA’s 14th Annual Fall Dermatology Conference, Dr. Craig Kraffert, MD conveyed patients want efficacious, easy to use treatments with minimal side effects. He stressed that long term control is a key goal for the treatment of these patients. Dr. Kraffert’s presentation included a live interview with a patient who has used Stelara® (ustekinumab) for the treatment of his plaque psoriasis. During the interview, Dr. Kraffert asked the patient “what is the best support that a provider can give to their psoriasis patient”. The patient responded “education including giving patients all of the options there are available for treatment”. The psoriasis patient’s recommendation for patients who have psoriasis is to seek a provider who takes “their condition seriously and who will work as a partner to find the best solution”.
Stelara® is indicated for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. This medication is given through subcutaneous injection and dosing is based on weight. Stelara® is an immunosuppressant medication and may increase the risk of infections, reactivation of latent infections (e.g. TB) and malignancies. Five years of efficacy and safety data from clinical trials reveal Stelara® as an option for patients with moderate to severe psoriasis who seek an option with efficacy, safety and ease of use.
Byline: Sarah Patton, PA-C, MSHS
Posted: November 6, 2016